Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AeroVanc for persistent MRSA lung infection in CF
NCT01746095Phase 2Completed
- Sponsor
- Savara
- Start
- Mar 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus infection comparing AeroVanc with Placebo (2 arms). Primary endpoint: Change From Baseline in MRSA Sputum Density at Day 29. Started Mar 2013; status: completed.
02
Drugs
aerosolized vancomycin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT01746095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746095.